A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Completed

Conditions studied: Myelofibrosis

In brief

The purpose of this study is to determine real-world patient-reported outcomes with fedratinib (FEDR) therapy for myelofibrosis (MF) in the real-world (RW) setting.

Key facts

Study ID

NCT05665192

Run by

Bristol-Myers Squibb

People needed

150

Starts

2021-08-02

Expected to finish

2023-07-24

Last updated by the study team

2025-04-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with Primary myelofibrosis (PMF), post- Essential thrombocythemia (ET) Myelofibrosis (MF), or post- Polycythemia vera (PV) MF
• Treated with FEDR and initiated treatment after 16 August 2019.
• Received prior treatment with RUX.
• Had spleen assessed at time of initiation of FEDR by palpation.
• Able to read and speak English
• Willing to provide informed consent
• Willing to provide permission to the site to release her/his medical information to the study investigators according to the study-specific eCRF
• Willing to complete the baseline survey prior to first FEDR

You may not qualify if…

• Past or current participant in any FEDR-related clinical trial

Where it is running

• Cardinal Health Specialty Solutions — Dublin, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.